buformin has been researched along with Hyperlipoproteinemia Type II in 1 studies
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korkushko, OV | 1 |
| Bogatskaia, LN | 1 |
| Kovalenko, AN | 1 |
| Novikova, SN | 1 |
| Kotko, DN | 1 |
1 other study available for buformin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
[Correction of dyslipoproteinemia in middle-aged and elderly patients with atherosclerosis using Essentiale in combination with adebit].
Topics: Aged; Aged, 80 and over; Biguanides; Buformin; Coronary Artery Disease; Drug Evaluation; Drug Therap | 1989 |